Gene therapies in the pipeline to treat hemophilia will be very expensive, but they also seem to be very efficacious, and multiple could hit the market between now and 2024, said Ray Tancredi, RPh, MBA, CSP, divisional vice president, specialty pharmacy development and brand Rx/vaccine purchasing, Walgreens.
Gene therapies in the pipeline to treat hemophilia will be very expensive, but they also seem to be very efficacious, and multiple could hit the market between now and 2024, said Ray Tancredi, RPh, MBA, CSP, divisional vice president, specialty pharmacy development and brand Rx/vaccine purchasing, Walgreens.
Transcript
There are a few gene therapies for hemophilia in the pipeline. What will it mean for the health care system if more than one of these expensive therapies is approved in the next 1 to 2 years?
Yeah, that's an interesting thought. When you think of the cell and gene products, you know, I saw 4 therapies for hemophilia A in the pipeline and 2 therapies for hemophilia B. They all have the potential to come to market between now and 2024. All of these products have similar labels upon approval—use limited to moderate to severe disease—and they're really comparable in safety and efficacy. And not only that, these products will really compete with drugs that are already entrenched in the marketplace, like Hemlibra, which is a long-acting factor replacement product.
So, this may create a market where the payers have to create formularies, maybe even have different patient evaluations for prior authorization. And the primary drivers will be: How do the manufacturer and the payers work together to use these products and ensure that that they're effective? I saw some stats in the New England Journal of Medicine; there was an 84% decrease in bleeds and a 99% decrease in factor use for BioMarin's hemophilia product.
So, I think they're efficacious. I don't know exactly what the costs will be, but you know they will be very expensive, and pharma and the payers and plan sponsors are all going to have to look at these therapies, evaluate their efficacy and the costs, and determine the best patients for these products to be used in.
But very exciting. When you think about hemophilia as a disease state, these products could change patients’ lives. So, it's very, very exciting, disruptive to the market, and it'll be great for patients to maybe reduce their use of factor products.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Posters Detail Effects—and Uncertainty—of Drug Pricing Negotiations
May 7th 2024Research into the Inflation Reduction Act evaluated payer concerns, patient and physician behavior, which patients will benefit from the first 10 drugs selected for price negotiation, and the ripple effect into Medicaid at the state level.
Read More